Fizazi, et al. ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC). ASCO-GU 2019, abstract 140.
Betere therapie voor cervixcarcinoom door afremmen DNA-reparatie tumorcellen
apr 2017 | Gynaecologische oncologie